CN102614129B - Enrofloxacin dry suspension - Google Patents
Enrofloxacin dry suspension Download PDFInfo
- Publication number
- CN102614129B CN102614129B CN2012101099369A CN201210109936A CN102614129B CN 102614129 B CN102614129 B CN 102614129B CN 2012101099369 A CN2012101099369 A CN 2012101099369A CN 201210109936 A CN201210109936 A CN 201210109936A CN 102614129 B CN102614129 B CN 102614129B
- Authority
- CN
- China
- Prior art keywords
- enrofloxacin
- dry suspension
- water
- suspension
- dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of antibiotic preparations for livestock and in particular discloses a dry suspension component containing enrofloxacin. The enrofloxacin dry suspension is prepared by the following steps: performing solid dispersion to the water-insoluble enrofloxacin; and mixing the enrofloxacin and auxiliary materials comprising suspending aid, wetting agent, diluent, sweetener, adsorbent and flow aid uniformly to prepare the enrofloxacin dry suspension which can be dispersed into water uniformly and is used for performing oral administration to livestock. The enrofloxacin dry suspension has the advantages of simple method, low cost, stable quality, good suspension effect in water, excellent palatability and the like. In addition, the enrofloxacin dry suspension has the advantages of convenience in use, long acting time of medicines, high bioavailability and the like.
Description
Technical field
The invention belongs to antibiotic formulations technical field for animals, be specifically related to a kind of dry suspension prescription, relate in particular to a kind of can be dispersed in water, can be for clinical oral administration administration, the enrofloxacin dry suspension that mouthfeel is good.
Background technology
Enrofloxacin is the fluoroquinolone antibacterial agent of animal specific, is broad spectrum antibiotic, have that has a broad antifungal spectrum, sterilizing power are strong, effect rapidly, in body widely distributed and with other antibiotics between without characteristics such as cross resistances, enjoy veterinary's circle attention.Be widely used at present control animal bacteria disease and mycoplasma both at home and abroad, yellow and white dysentery of piglet, bowel oedema disease, mycoplasma pneumoniae of swine, mycoplasma gallinarum disease, avian colibacillosis, Pullorum Disease etc. are all had to significant curative effect.
In home poultry raising, poultry-farm or specialist often adopt the mode of oral administration to carry out fowl diseases prevention and treatment, because oral administration is easy, time saving and energy saving, can reduce or avoid the poultry stress simultaneously.Because enrofloxacin itself has in water poorly soluble, bitter in the mouth, the shortcoming that palatability is poor, clinical practice both at home and abroad at present is multiplex in to the insensible chicken of bitterness in oral enrofloxacin solution, is not used in the animals such as pig of sense of taste sensitivity, for example, the enrofloxacin soluble powder is in the use procedure of mixed drink, usually because its palatability is bad, drinking refusal causes the waste of medicine and the delay of the state of an illness to pig, thereby has affected convenience and the economy of its use.
Dry suspension is that slightly solubility solid drugs and proper auxiliary materials are made to powder or shot-like particle, faces the used time to add the water jolting and can be dispersed into suspensoid for orally using.With pre-mixing agent or powder, compare, it adds water while using can become solution, and is uniformly dispersed.Because of incomplete mixing, or search for food to descend after the poultry morbidity and cause drug effect undesirable when having overcome pre-mixing agent or powder spice and using, also avoided taking the feedstuff that local drug concentration is high and caused poisoning phenomenon; Dry suspension is large than the specific surface area of pre-mixing agent simultaneously, absorbs rapidly, and bioavailability is high, and cure rate is higher.With the solution ratio, due to it, all the time in dry anhydrous state, stability more easily realizes.In addition, dry suspension is easy to use, has saved a large amount of manpower and materials.
Yet the enrofloxacin crude drug is very bitter, must be very bitter if make dry suspension according to routine techniques, be difficult to swallow, cause the poultry refusing to eat.Therefore, how can effectively overcome and cover bitterness, also guarantee that adding water can form homodisperse suspension, be the key issue for preparing the enrofloxacin dry suspension.
Summary of the invention
For the deficiencies in the prior art, a kind of filler before use clothes have been the object of the present invention is to provide, dispersibility and good palatability, strong drug action, the enrofloxacin dry suspension of long action time.
Technical conceive of the present invention is by adding solid dispersible carrier, suspending agent, wetting agent, guarantees that preparation suspendible when adding water is even; By adding a certain proportion of sweeting agent and a certain proportion of adsorbent to cover the bitterness of enrofloxacin, increase the compliance of sense of taste Sensitivity animal again; Add again the mobility of powder in fluidizer assurance preparation process, reach the purpose of mix homogeneously, finally add diluent and obtain product.
The technical solution used in the present invention is as follows:
A kind of enrofloxacin dry suspension is prepared from by the raw material of following percentage by weight:
Enrofloxacin 2.5-10%,
Solid dispersible carrier 10-35%,
Suspending agent 15-30%,
Wetting agent 4-10%,
Sweeting agent 2-10%,
Adsorbent 2.5-5%,
Fluidizer 0.05-0.15%,
Diluent 10-63.45%.
Preferably, a kind of enrofloxacin dry suspension is prepared from by the raw material of following percentage by weight:
Enrofloxacin 2.5-7.5%,
Solid dispersible carrier 10-30%,
Suspending agent 15-30%,
Wetting agent 4-10%,
Sweeting agent 2.5-8%,
Adsorbent 2.5-5%,
Fluidizer 0.05-0.15%,
Diluent 15-63.45%.
More excellent, a kind of enrofloxacin dry suspension is prepared from by the raw material of following percentage by weight:
Enrofloxacin 3-6%,
Solid dispersible carrier 10-20%,
Suspending agent 15-25%,
Wetting agent 8-10%,
Sweeting agent 3-6%,
Adsorbent 3-5%,
Fluidizer 0.05-0.1%,
Diluent 30-50%.
Best, a kind of enrofloxacin dry suspension is prepared from by the raw material of following percentage by weight:
Enrofloxacin 5%,
Solid dispersible carrier 15%,
Suspending agent 20%,
Wetting agent 10%,
Sweeting agent 5%,
Adsorbent 5%,
Fluidizer 0.075%,
Diluent 39.925%.
Wherein, the solid dispersible carrier is selected from one or more in Macrogol 4000, beta-schardinger dextrin-, carbamide.
Suspending agent is selected from one or more in sodium carboxymethyl cellulose, xanthan gum, hydroxypropyl emthylcellulose, arabic gum.
Wetting agent is selected from one or more in sodium lauryl sulphate, PLURONICS F87, polyoxyethylene stearate (40) ester.
Sweeting agent is selected from one or more in saccharin sodium, stevioside, aspartame, cyclamate, acesulfame-K, requires its granularity >=100 orders.
Adsorbent is alkaline earth oxide or alkaline earth metal hydroxide, preferential oxidation magnesium.
Fluidizer is selected from one or more in micropowder silica gel, Pulvis Talci, magnesium stearate, preferably micropowder silica gel.
Diluent is selected from one or more in anhydrous glucose, lactose, Matrii Sulfas Exsiccatus, sucrose.
The preparation method of enrofloxacin dry suspension of the present invention is by after enrofloxacin crude drug, solid dispersible carrier, suspending agent, the abundant mix homogeneously of wetting agent, is crushed to and all crosses 200 mesh sieves; Then the mixture after sieving is fully mixed homogeneously with sweeting agent, adsorbent, fluidizer, diluent, packing and get final product.
Compared with prior art, advantage of the present invention and beneficial effect are:
1, the present invention is by adding sweeting agent and adsorbent, faces the used time to add water, and mouthfeel is better, can cover well the bitterness of enrofloxacin itself; Improved the limitation that enrofloxacin can not be oral due to bitter in the mouth on the disease for the treatment of pig, and do not affected pig and search for food.
2, the present invention, by solid dispersion technology, has significantly improved the dispersibility of enrofloxacin in water, can be dispersed in for a long time in water, facilitates oral administration.
3, product of the present invention has long-acting, can reduce administration number of times, saves the labour; And preparation technology is simple, production cost is low, is applicable to industrialized great production.
The specific embodiment
Following applicant is described in detail product of the present invention in connection with specific embodiment, so that those skilled in the art has further and understands the present invention, but following examples are interpreted as limiting the scope of the invention never in any form.
Embodiment 1:
A kind of enrofloxacin dry suspension is prepared from by the raw material of following formula:
| Raw material | Consumption |
| The enrofloxacin crude drug | 2.5g |
| Macrogol 4000 | 10g |
| Sodium carboxymethyl cellulose | 15g |
| Sodium lauryl sulphate | 4g |
| Cyclamate (granularity >=100 orders) | 2.5g |
| Magnesium oxide | 2.5g |
| Micropowder silica gel | 0.05g |
| Matrii Sulfas Exsiccatus | 63.45g |
The total amount of above-mentioned raw materials is 100g.
Compound method: by after the abundant mix homogeneously of enrofloxacin crude drug, Macrogol 4000, sodium carboxymethyl cellulose, sodium lauryl sulphate of above-mentioned formula ratio, be crushed to and all cross 200 mesh sieves, then the mixture after sieving is mixed homogeneously and be get final product with cyclamate, magnesium oxide, micropowder silica gel, the Matrii Sulfas Exsiccatus of above-mentioned formula ratio.
Add before use water, oral getting final product, following examples 2-5 is same.
Embodiment 2:
A kind of enrofloxacin dry suspension is prepared from by the raw material of following formula:
| Raw material | Consumption |
| The enrofloxacin crude drug | 5g |
| Beta-schardinger dextrin- | 10g |
| Carbamide | 5g |
| Sodium carboxymethyl cellulose | 20g |
| Polyoxyethylene stearate (40) ester | 10g |
| Aspartame (granularity >=100 orders) | 5g |
| Magnesium oxide | 5g |
| Micropowder silica gel | 0.075g |
| Anhydrous glucose | 39.925g |
The total amount of above-mentioned raw materials is 100g.
Compound method: by after the enrofloxacin crude drug of above-mentioned formula ratio, beta-schardinger dextrin-, carbamide, sodium carboxymethyl cellulose, the abundant mix homogeneously of polyoxyethylene stearate (40) ester, be crushed to and all cross 200 mesh sieves, then the mixture after sieving is mixed homogeneously and be get final product with aspartame, magnesium oxide, micropowder silica gel, the anhydrous glucose of above-mentioned formula ratio.
Embodiment 3:
A kind of enrofloxacin dry suspension is prepared from by the raw material of following formula:
| Raw material | Consumption |
| The enrofloxacin crude drug | 5g |
| Beta-schardinger dextrin- | 15g |
| Xanthan gum | 20g |
| Sodium lauryl sulphate | 10g |
| Stevioside (granularity >=100 orders) | 6g |
| Magnesium oxide | 5g |
| Micropowder silica gel | 0.075g |
| Matrii Sulfas Exsiccatus | 38.925g |
The total amount of above-mentioned raw materials is 100g.
Compound method: by after the abundant mix homogeneously of enrofloxacin crude drug, beta-schardinger dextrin-, xanthan gum, sodium lauryl sulphate of above-mentioned formula ratio, be crushed to and all cross 200 mesh sieves, then the mixture after sieving is mixed homogeneously and be get final product with stevioside, magnesium oxide, micropowder silica gel, the Matrii Sulfas Exsiccatus of above-mentioned formula ratio.
Embodiment 4:
A kind of enrofloxacin dry suspension is prepared from by the raw material of following formula:
| Raw material | Consumption |
| The enrofloxacin crude drug | 7.5g |
| Beta-schardinger dextrin- | 15g |
| Carbamide | 15g |
| Arabic gum | 15g |
| Sodium carboxymethyl cellulose | 15g |
| Polyoxyethylene stearate (40) ester | 6g |
| Acesulfame-K (granularity >=100 orders) | 7g |
| Magnesium oxide | 5g |
| Micropowder silica gel | 0.1g |
| Lactose | 14.4g |
The total amount of above-mentioned raw materials is 100g.
Compound method: by after the enrofloxacin crude drug of above-mentioned formula ratio, beta-schardinger dextrin-, carbamide, arabic gum, sodium carboxymethyl cellulose, the abundant mix homogeneously of polyoxyethylene stearate (40) ester, be crushed to and all cross 200 mesh sieves, then the mixture after sieving is mixed homogeneously and be get final product with acesulfame-K, magnesium oxide, micropowder silica gel, the lactose of above-mentioned formula ratio.
Embodiment 5:
A kind of enrofloxacin dry suspension is prepared from by the raw material of following formula:
| Raw material | Consumption |
| The enrofloxacin crude drug | 10g |
| Beta-schardinger dextrin- | 15g |
| Carbamide | 20g |
| Xanthan gum | 5g |
| Hydroxypropyl emthylcellulose | 20g |
| PLURONICS F87 | 5g |
| Saccharin sodium (granularity >=100 orders) | 8g |
| Magnesium oxide | 5g |
| Micropowder silica gel | 0.15g |
| Anhydrous glucose | 11.85g |
The total amount of above-mentioned raw materials is 100g.
Compound method: by after enrofloxacin crude drug, beta-schardinger dextrin-, carbamide, xanthan gum, hydroxypropyl emthylcellulose, the abundant mix homogeneously of PLURONICS F87, be crushed to and all cross 200 mesh sieves, then the mixture after sieving is mixed homogeneously and be get final product with saccharin sodium, magnesium oxide, micropowder silica gel, anhydrous glucose.
Embodiment 6: settling volume is than measuring
In order to measure the dispersibility of preparation of the present invention in water, requirement according to " People's Republic of China's veterinary drug allusion quotation ", product to embodiment 1, embodiment 2, embodiment 3, embodiment 4, embodiment 5 carries out settling volume than measuring, getting respectively this product 0.25g puts in tool plug graduated cylinder, add water to 50mL, airtight, firmly jolting 1min, write down the height H that suspended matter starts
0, after standing 3 hours, write down the final height H of suspended matter, be calculated as follows; Settling volume ratio=H/H
0, the settling volume ratio should be not less than 0.90.
The measurement result demonstration, the sample of embodiment 1-embodiment 5, even, after placing 24 hours by above-mentioned requirements, settling volume still is greater than 0.98 than all, illustrate that the present invention has good suspendible effect.
Experimental example 7: stability test
Accelerated test
In order to measure the stability of preparation, requirement according to " veterinary drug stability test technical specification ", accelerated test under ad hoc fixed following condition, the dry suspension that embodiment 1, embodiment 2, embodiment 4, embodiment 5 are made is 40 ± 2 ℃ of temperature, under the condition of relative humidity 75 ± 5%, place 6 months, sampling in 0,1,2,3,6 month once, investigated by stability high spot reviews project respectively, investigated character, settling volume ratio, content.The results are shown in Table 1-table 4.
The dry suspension accelerated stability test result of table 1 embodiment 1
| Time | Content (%/w) | Appearance character | The settling volume ratio |
| 0 month | 2.53 | Off-white powder | 1.00 |
| January | 2.51 | Off-white powder | 0.99 |
| February | 2.52 | Off-white powder | 0.99 |
| March | 2.51 | Off-white powder | 0.98 |
| June | 2.49 | Off-white powder | 0.96 |
The dry suspension accelerated stability test result of table 2 embodiment 2
| Time | Content (%/w) | Appearance character | The settling volume ratio |
| 0 month | 5.06 | Off-white powder | 1.00 |
| January | 5.04 | Off-white powder | 0.98 |
| February | 5.05 | Off-white powder | 0.96 |
| March | 5.02 | Off-white powder | 0.95 |
| June | 4.98 | Off-white powder | 0.94 |
The dry suspension accelerated stability test result of table 3 embodiment 4
| Time | Content (%/w) | Appearance character | The settling volume ratio |
| 0 month | 7.59 | Off-white powder | 1.00 |
| January | 7.56 | Off-white powder | 0.97 |
| February | 7.55 | Off-white powder | 0.96 |
| March | 7.52 | Off-white powder | 0.95 |
| June | 7.48 | Off-white powder | 0.94 |
The dry suspension accelerated stability test result of table 4 embodiment 5
| Time | Content (%/w) | Appearance character | The settling volume ratio |
| 0 month | 10.10 | Off-white powder | 1.00 |
| January | 10.08 | Off-white powder | 0.96 |
| February | 10.04 | Off-white powder | 0.95 |
| March | 9.99 | Off-white powder | 0.94 |
| June | 9.89 | Off-white powder | 0.92 |
From testing result, the enrofloxacin dry suspension of embodiment 1, embodiment 2, embodiment 4, embodiment 5 is at accelerated stability test in the phase, and character does not all change, settling ratio all is greater than 0.9, content does not have significant change, and indices meets the requirements, and this product good stability is described.
Experimental example 8: enrofloxacin dry suspension of the present invention is to the yellow and white dysentery of piglet clinical effect trial
Control drug: commercially available 2.5% enrofloxacin solution, Guangzhou favour China animal health-care product company limited is produced.
Trial drug: the enrofloxacin dry suspension of the present embodiment 2 preparation, face the used time to be dissolved in water into suspension solution.
Test method: choose 120 of the piglets that HUANGBAI(sic) dysentery symptom is arranged, body weight 10 ± 2kg, be divided into 3 groups at random, is respectively test I group, contrast II group, blank III group, 40 every group.Test I group, by 5mg/kg (enrofloxacin) oral test medicine group, every day 1 time, is used in conjunction 5 days; Contrast II group, by the oral control drug of 2.5mg/kg (enrofloxacin), every day 2 times, is used in conjunction 5 days; Blank III group, not administration.
Result of the test: according to the enrofloxacin dry suspension of embodiment 2 preparations and the clinical effect trial of control drug, the results are shown in Table 5:
In process of the test, test I group piglet recovers the fastest, and feed intake, the mental status are clearly better, and without bad side reaction, the average daily ingestion amount of curing piglet is close with the normal piglets of not falling ill; Contrast II group effect, inferior to test I group, in the piglet that sb.'s illness took a favorable turn, part piglet refusing to eat phenomenon occurs, and the average daily ingestion amount of curing piglet is starkly lower than the healing piglet of test I group; Blank III group is no matter in feed intake or the mental status obviously is worse than test I group, contrast II group.
Brief summary: enrofloxacin dry suspension of the present invention is for the Piglet by Oral administration, and good palatability, affect the normal feed intake of piglet hardly; Evident in efficacy, be conducive to disease treatment, and preparation has certain long-acting, can reduce administration number of times, save the labour.
Claims (1)
1. an enrofloxacin dry suspension, preparation method is as follows:
By after enrofloxacin crude drug 5g, beta-schardinger dextrin-10g, carbamide 5g, sodium carboxymethyl cellulose 20g, the abundant mix homogeneously of polyoxyethylene stearate (40) ester 10g, be crushed to and all cross 200 mesh sieves, then the mixture after sieving is mixed homogeneously and be get final product with aspartame 5g, magnesium oxide 5g, micropowder silica gel 0.075g, anhydrous glucose 39.925g, the granularity of described aspartame >=100 orders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101099369A CN102614129B (en) | 2012-04-16 | 2012-04-16 | Enrofloxacin dry suspension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101099369A CN102614129B (en) | 2012-04-16 | 2012-04-16 | Enrofloxacin dry suspension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102614129A CN102614129A (en) | 2012-08-01 |
| CN102614129B true CN102614129B (en) | 2013-12-11 |
Family
ID=46554585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101099369A Active CN102614129B (en) | 2012-04-16 | 2012-04-16 | Enrofloxacin dry suspension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614129B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103054808B (en) * | 2012-12-27 | 2014-09-24 | 成都乾坤动物药业有限公司 | Tilmicosin dry suspension, method for preparing dry suspension and uses thereof |
| CN103222975B (en) * | 2013-05-03 | 2014-12-17 | 广州英赛特生物技术有限公司 | Application of enrofloxacin salt in preparation of swine oral preparation |
| CN103520188B (en) * | 2013-10-23 | 2015-09-02 | 成都乾坤动物药业有限公司 | A kind of poultry compound antibacterial dry suspension and preparation method thereof |
| CN103655479B (en) * | 2013-12-12 | 2015-12-09 | 成都乾坤动物药业有限公司 | A kind of andrographolide composition wettability solid dispersal powder and preparation method thereof |
| CN103800354A (en) * | 2013-12-24 | 2014-05-21 | 沈阳伟嘉牧业技术有限公司 | Compound albendazole dry suspension and preparation method thereof |
| CN104188919B (en) * | 2014-09-25 | 2018-01-26 | 河南亚卫动物药业有限公司 | A kind of livestock and poultry Thiamphenicol dried bean noodles supensoid agent and preparation method thereof |
| CN106038482A (en) * | 2016-07-15 | 2016-10-26 | 华南农业大学 | Enrofloxacin uterus perfusion liquid as well as preparation method and application thereof |
| CN107349182A (en) * | 2017-05-31 | 2017-11-17 | 合肥中龙神力动物药业有限公司 | Animal enrofloxacin suspension and preparation method thereof |
| CN107823132A (en) * | 2017-11-23 | 2018-03-23 | 湖北龙翔药业科技股份有限公司 | A kind of Marbofloxacin suspension and preparation method thereof |
| CN117771175B (en) * | 2024-02-23 | 2024-06-07 | 中国农业科学院农业环境与可持续发展研究所 | Enrofloxacin nano suspension and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457782A (en) * | 2003-05-17 | 2003-11-26 | 南昌弘益科技有限公司 | Dry spaxxacin suspension agent for resisting bacterial infection and its preparing method |
| CN1706386A (en) * | 2005-04-29 | 2005-12-14 | 史同瑞 | Enrofloxacin suspension and its prepn process |
| CN102274189A (en) * | 2011-07-21 | 2011-12-14 | 瑞普（天津）生物药业有限公司 | Decoquinate-containing suspension formula and preparation method thereof |
-
2012
- 2012-04-16 CN CN2012101099369A patent/CN102614129B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457782A (en) * | 2003-05-17 | 2003-11-26 | 南昌弘益科技有限公司 | Dry spaxxacin suspension agent for resisting bacterial infection and its preparing method |
| CN1706386A (en) * | 2005-04-29 | 2005-12-14 | 史同瑞 | Enrofloxacin suspension and its prepn process |
| CN102274189A (en) * | 2011-07-21 | 2011-12-14 | 瑞普（天津）生物药业有限公司 | Decoquinate-containing suspension formula and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘小艳等.恩诺沙星口服混悬液的研制及其对仔猪黄白痢疗的效观察.《动物医学进展》.2009,第30卷(第9期),120-122. |
| 吴海坤等.恩诺沙星混悬液的研制及其在鸡组织中的残留研究.《动物医学进展》.2010,第31卷(第4期),47-52页. |
| 恩诺沙星口服混悬液的研制及其对仔猪黄白痢疗的效观察;刘小艳等;《动物医学进展》;20090920;第30卷(第9期);120-122 * |
| 恩诺沙星混悬液的研制及其在鸡组织中的残留研究;吴海坤等;《动物医学进展》;20100420;第31卷(第4期);47-52页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102614129A (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614129B (en) | Enrofloxacin dry suspension | |
| CN102949348B (en) | Enramycin dry suspension and preparation method thereof | |
| CN103054808B (en) | Tilmicosin dry suspension, method for preparing dry suspension and uses thereof | |
| CN101999558B (en) | Compound premix for pigs at different physiological stages | |
| CN103830187A (en) | Tilmicosin solid dispersible granule as well as preparation method and application thereof | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN104814931B (en) | A kind of olaquindox slow-releasing granules and its preparation method and application | |
| CN102274189A (en) | Decoquinate-containing suspension formula and preparation method thereof | |
| CN107375247B (en) | Tilmicosin film-controlled enteric sustained-release preparation and preparation method thereof | |
| CN104906121A (en) | Tildipirosin-containing medicinal composition | |
| CN103301463A (en) | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases | |
| CN103239422A (en) | Preparation method of smellless coated enrofloxacin preparation | |
| CN107595871A (en) | Compound preparation containing ivermectin and preparation method thereof | |
| CN102846641A (en) | Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry | |
| CN107550867B (en) | Antistatic tavermectin tartrate premix and preparation method thereof | |
| CN111296655A (en) | Application of licoflavone raw powder in nursing material for promoting intestinal health of weaned pigs | |
| CN104027369A (en) | Plumbago zeylanica and norfloxacin containing compound composition for livestock and poultry | |
| CN112535664A (en) | Water-soluble tilmicosin premix and preparation method thereof | |
| CN103536604B (en) | A kind of wettable sulfamethoxazole trimethoprim powder and preparation method thereof | |
| CN103520188B (en) | A kind of poultry compound antibacterial dry suspension and preparation method thereof | |
| CN101011362A (en) | Dispersible tablet of pidotimod and its preparing process and use | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN102247390B (en) | Medicine for treating bacterial air sacculitis in livestock and preparation method thereof | |
| CN103432076A (en) | Cefprozil dry suspension and preparation method thereof | |
| CN106924198A (en) | Doxycycline hydrochloride oral disintegrating tablet for domestic fowls and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 430042 Hubei province Dongxihu District of Wuhan City Road No. 208 Zhang Patentee after: Wuhan Sheng Sheng biological Polytron Technologies Inc Address before: 430042 Hubei province Dongxihu District of Wuhan City Road No. 208 Zhang Patentee before: Wuhan Hvsen Biotechnology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190428 Address after: 410011 No. 107 Kangtian Road, Liuyang Economic and Technological Development Zone, Changsha City, Hunan Province Patentee after: Changsha SPN Animal Pharmaceutical Co., Ltd. Address before: 430042 No. 208 Zhangbai Road, Dongxihu District, Wuhan City, Hubei Province Patentee before: Wuhan Sheng Sheng biological Polytron Technologies Inc |